Special Considerations in the Management of HIV-Infected Patients From Minority Communities

  • Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
  • Section Editor: Judith S. Currier, MD, MSc
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/9/18 (What's New)

Summary

  • WHO guidelines recommend giving oral tenofovir DF–containing PrEP with other preventive strategies to patients with substantial risk of HIV infection including subgroups of MSM and transgender women[WHO 2016]
  • Several clinical trials enrolling MSM and transgender women have demonstrated high efficacy of emtricitabine/tenofovir DF given as PrEP[McCormack 2016; Molina 2015]
  • Adherence is generally high in patients engaging in high risk behaviors[Liu 2016; Hosek 2017]

    Action required

    Keywords: Minority-Ethnic Communities, Special Populations

    ©2020 Clinical Care Options, LLC. All Rights Reserved.

    The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.